Goodrx is trading 6.4% up now at $3.48 after its August 5, 2026, second-quarter results beat revenue expectations and management raised full-year 2026 revenue guidance to $790 million–$805 million.
- Pharma Direct revenue surged 76% to $61.6 million, supported by GLP-1 access programs.
- Adjusted EBITDA reached $63.7 million, making the earnings beat and improved outlook the clearest catalysts for the opening-session gain.